The report covers the present scenario and the growth prospects of the Europe Blood Screening Market for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major players in the market.
Various techniques are available in the market to perform assays for detection of the problems related to health is Immunoassays (IAs) and Nucleic Acid Amplification Technology (NAT) assays. Immunoassay is categorized into enzyme immunoassays (EIAs), chemiluminescent immunoassays (CLIAs), haemagglutination (HA)/particle agglutination (PA) assays and rapid/simple single-use assays (rapid tests).
Screening process can also be called as the first line of defense in health care field providing a safe blood supply and also helping in minimizing the problems associated with transfusion-transmitted infection. Government associations from every country should establish blood donor programs to provide information and education about blood donations.
Some of the prominent participants operating in this market are Enzo Biochem Inc. , Meridian Bioscience, Inc. , BD , Bio-Rad Laboratories, Inc. , Thermo Fisher Scientific Inc. , BioMérieux SA , Beckman Coulter, Inc. , Abbott , F. Hoffmann-La Roche Ltd , Cepheid , GRIFOLS INTERNATIONAL, S.A. , Siemens AG (Germany), Ortho Clinical Diagnostics , Immucor, Inc., Hologic Inc. , among others.
Europe blood screening market is projected to register a healthy CAGR of 9.3% in the forecast period of 2018 to 2025.
The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.
Get a Copy of Sample Report Now! @ https://databridgemarketresearch.com/request-a-sample/?dbmr=europe-blood-screening-market
Market Segmentation: Europe Blood Screening Market
The Global Blood Screening Market is categorized based on the basis of products & services, technology, disease type and end user.
On the basis of product & services the market is segmented into reagents & kits, instruments and also software & services. Reagents & kits are further sub segmented into NAT reagents & kits, ELISA reagents & kits and other reagents. NAT reagents are further sub segmented into enzymes and polymerases, standards and controls, probes and primers, buffers, nucleotides and solutions and labeling and detection reagents.
On the basis of technology the market is segmented into nucleic acid test, enzyme-linked immunosorbent assay (ELISA), rapid tests, western blot assay, next-generation sequencing (NGS) and others. Nucleic acid test is further sub segmented into transcription-mediated amplification (TMA) and real-time polymerase chain reaction (PCR).
Enzyme-linked immunosorbent assay (ELISA) are further segmented into ELISA market, by platform, ELISA market, by generation. ELISA Market, By Platform is further sub segmented into chemiluminescence immunoassay (CLIA), fluorescence immunoassay (FIA) and colorimetric immunoassay (CI).
On the basis of disease type, the market is segmented into respiratory diseases, diabetes mellitus, oncology, cholesterol, HIV/AIDS, cold & flu, infectious diseases and others. In 2017, oncology segment is expected to dominate the global blood screening market growing at the highest CAGR of 10.3% in the forecast period of 2018 to 2025.
On the basis of end user the market is segmented into hospitals, clinics, diagnostic centers, blood bank and ambulatory surgical cenetrs. In 2017, diagnostic centers segment is expected to dominate the global blood screening market growing at the highest CAGR of 10.4%in the forecast period of 2018 to 2025.
Inquiry Before Buying and Discuss Report Customization with Industry Expert @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=europe-blood-screening-market
Key points for analysis
- To get a comprehensive overview of the market.
- To gain information about the top players in this industry, their product portfolios, and their key strategies.
- To gain insights about the major regional insights in which the is flourishing.
- Recent industry trends and developments
- Potential and niche segments/regions exhibiting promising growth
Benefits of the report for market
- What are the challenges being faced by the new entrants
- Drivers and restrains of the market
- Key developments in the market
- Market volume
- CAGR value for the forecast period 2018-2025
Product launch: Europe Blood Screening Market
In March 2018, Bio-Rad Laboratories, Inc. launched IncRNA Workflow, a RT-qPCR workflow which is used optimized for highly sensitive and specific quantification of long noncoding RNAs (lncRNAs) for gene expression analysis. The workflow provides a streamlined, cost-effective alternative to RNA-Seq for lncRNA discovery and validation
In June 2018, Thermo Fisher Scientific launched Oncomine TCR Beta-SR Assay. It is a new next-generation sequencing (NGS) solution in the field of immuno-oncology research. This helped company to expand their business by enhancing their product portfolio.
Speak to Analyst and Get Free Customized Information about Report @ https://databridgemarketresearch.com/speak-to-analyst/?dbmr=europe-blood-screening-market
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge Market Research